Increased tumor uptake of 3-(123)I-Iodo-L-alpha-methyltyrosine after preloading with amino acids: an in vivo animal imaging study.

UNLABELLED 3-(123)I-Iodo-L-alpha-methyltyrosine (3-IMT) is an amino acid analog used for tumor imaging. Specific accumulation is mediated mainly by the system L amino acid transport system. System L activity is known to increase when cells are loaded with amino acids. The aim of our study was to measure the effects of amino acid preload on (123)I-3-IMT tumor uptake and image contrast in a rat tumor model using in vivo dynamic imaging. METHODS Rhabdomyosarcoma (R1M) tumor-bearing rats underwent 2 dynamic (123)I-3-IMT studies on separate days: 1 baseline study and 1 after intraperitoneal injection (0.25 mmol/kg) of a single amino acid (arginine, proline, glutamate, asparagine, tryptophan, or phenylalanine) administered 30 min before intravenous injection of 18.5 MBq (123)I-3-IMT. A (99m)Tc-labeled human serum albumin study was performed on each rat for the calculation of the blood-pool activity inside the tumor. Time-activity curves were generated for tumor, contralateral background region, kidney, heart, and total body. Tumor uptake was corrected for blood-pool and background activity. Image contrast was calculated as the ratio between tumor and background activity. The rate (K(1)) of tracer entering the tumor was obtained using Patlak analysis. A displacement study was performed on a separate group of rats, in which a high dose of phenylalanine was administered 40 min after (123)I-3-IMT injection. RESULTS (123)I-3-IMT accumulation in tumor reached a plateau 10 min after injection. Tumor uptake on the baseline scans correlated well with tumor size (r = 0.92). After preloading, tumor uptake and contrast increased in all conditions: arginine, +26% and +26%; proline, +15% and +13%; glutamate, +14% and +9%; asparagine, +19% and +15%; tryptophan, +36% and 11%; phenylalanine, +22% and + 13%. K(1) values also increased. Administration of an afterload with phenylalanine induced a significant displacement of (123)I-3-IMT tumor accumulation. CONCLUSION Prior amino acid administration increases (123)I-3-IMT tumor accumulation and image contrast. This effect can be explained by the increased antiporter activity of the amino acid transport system L in preloaded conditions. Our results indicate that the fasted state might not be the optimal metabolic condition to study tumor accumulation of L-transported tracers such as (123)I-3-IMT. Amino acid administration before (123)I-3-IMT injection could improve tumor uptake and image contrast.

[1]  M. Schwaiger,et al.  Correlation Between Postoperative 3-[123I]Iodo-l-α-Methyltyrosine Uptake and Survival in Patients with Gliomas , 2001 .

[2]  C. Vanhove,et al.  Diagnosis of recurrent head and neck squamous cell carcinoma with 3-[123I]iodo-L-α-methyltyrosine SPET , 2001, European Journal of Nuclear Medicine.

[3]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  A. Bossuyt,et al.  In vitro characterization of the influx of 3-[125I]iodo-L-alpha-methyltyrosine and 2-[125I]iodo-L-tyrosine into U266 human myeloma cells: evidence for system T transport. , 2001, Nuclear medicine and biology.

[5]  E. de Vries,et al.  Uptake mechanisms of L-3-[125I]iodo-alpha-methyl-tyrosine in a human small-cell lung cancer cell line: comparison with L-1-[14C]tyrosine , 2001, Nuclear medicine communications.

[6]  K. Langen,et al.  3-[123I]iodo-alpha-methyl-L-tyrosine transport and 4F2 antigen expression in human glioma cells. , 2001, Nuclear medicine and biology.

[7]  M. Schwaiger,et al.  Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  N. Thompson,et al.  TA1/LAT-1/CD98 Light Chain and System L Activity, but Not 4F2/CD98 Heavy Chain, Respond to Arginine Availability in Rat Hepatic Cells , 2000, The Journal of Biological Chemistry.

[9]  I. Paulsen,et al.  New Glycoprotein-Associated Amino Acid Transporters , 1999, The Journal of Membrane Biology.

[10]  M. Schwaiger,et al.  Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  L. Kühn,et al.  Amino acid transport of y+L‐type by heterodimers of 4F2hc/CD98 and members of the glycoprotein‐associated amino acid transporter family , 1999, The EMBO journal.

[12]  H. Groen,et al.  Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  H. Biersack,et al.  Simple preparation of l-3-Iodo-α-methyl tyrosine suitable for use in kit preparations , 1995 .

[14]  Peters Am,et al.  Graphical analysis of dynamic data: the Patlak-Rutland plot. , 1994 .

[15]  A. Peters Graphical analysis of dynamic data: the Patlak-Rutland plot. , 1994, Nuclear medicine communications.

[16]  H. Herzog,et al.  Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  H. Coenen,et al.  Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  H. Christensen,et al.  Organic ion transport during seven decades. The amino acids. , 1984, Biochimica et biophysica acta.

[19]  H. Christensen,et al.  Intensified gradients for endogenous amino acid substrates for transport system L on injecting a specific competitor for that system. , 1981, Life sciences.

[20]  D A Goldstein,et al.  The flow of solute and solvent across a two-membrane system. , 1963, Journal of theoretical biology.